
Clinical Development
Healing from the inside out.
At the center of our innovation is plasminogen — a protein the body naturally produces to clear damaged tissue, fight infection, and regenerate skin. Diseases like diabetes, kidney failure, or immune disorders can disrupt this process, resulting in chronic, non-healing wounds. Our therapy helps restore the body’s ability to heal.
Plasminogen is made primarily in the liver and circulates in your blood. When injury occurs, your body sends it to the wound site, where it’s converted into plasmin — a powerful enzyme that breaks down damaged tissue and kickstarts regeneration. This conversion is triggered by activators like tPA and uPA, which are naturally present in healing tissue.
In people with chronic conditions, this system breaks down. Omnio delivers a purified form of recombinant plasminogen directly to the wound site, reactivating all four phases of healing: Inflammation, proliferation, remodeling, and defense against infection.
Clinical Trials
Our therapy is moving into Phase IIa/IIb clinical trials for diabetic foot ulcers.
Preclinical studies have shown strong safety, efficacy, and healing acceleration in both standard and antibiotic-resistant wound models.
More information on study criteria and timelines will be available soon.
Research Collaborations
Omnio maintains close ties with research teams and academic institutions in Umeå, Sweden, where our technology was first developed.
We continue to collaborate on new data, translational studies, and expanded applications for plasminogen in regenerative medicine.
If you’re a researcher, clinician, or academic partner interested in collaboration, we’d love to hear from you.